<DOC>
	<DOC>NCT01125995</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status Small-cell lung cancer.</brief_summary>
	<brief_title>Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>histologically confirmed smallcell lung cancer limited disease status with evaluable disease 18 years or older ECOG performance status 0,1,2 expected survival time should be 12 weeks or longer Adequate organ function as evidenced by the following; Absolute neutrophil count &gt; 1.5 x 109/L; platelets &gt; 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT &lt; 5 UNL; creatinine clearance ≥ 50mL/min Written informed consent form 1. Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia 2. Patients with active infection requiring antibiotics 3. Pregnant or nursing women ( Women of reproductive potential have to agree to use an effective contraceptive method) 4. Prior history of malignancy within 5 years from study entry except for a adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, welltreated thyroid cancer 5. previous history of chemotherapy or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>limited disease</keyword>
</DOC>